Assertio Therapeutics Inc Asset Resilience Ratio
Assertio Therapeutics Inc asset resilience ratio. Assertio Therapeutics Inc (ASRT) has an Asset Resilience Ratio of 17.92% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ASRT defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Assertio Therapeutics Inc (1999–2025)
Asset resilience ratio of Assertio Therapeutics Inc from 1999 to 2025. This chart shows how Assertio Therapeutics Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Assertio Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Assertio Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ASRT total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $37.86 Million | 17.92% |
| Total Liquid Assets | $37.86 Million | 17.92% |
Asset Resilience Insights
- Good Liquidity Position: Assertio Therapeutics Inc maintains a healthy 17.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Assertio Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Assertio Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Assertio Therapeutics Inc Asset Resilience Ratio by Year (1999–2025)
Assertio Therapeutics Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Assertio Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.92% | $53.18 Million | $266.97 Million | +2.55pp |
| 2024-12-31 | 17.37% | $49.47 Million | $284.73 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $286.42 Million | -- |
| 2020-12-31 | 0.52% | $1.58 Million | $303.27 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $932.87 Million | -- |
| 2017-12-31 | 0.12% | $1.21 Million | $1.04 Billion | -4.76pp |
| 2016-12-31 | 4.87% | $59.71 Million | $1.23 Billion | -3.10pp |
| 2015-12-31 | 7.97% | $108.68 Million | $1.36 Billion | -1.98pp |
| 2014-12-31 | 9.95% | $70.77 Million | $711.07 Million | +4.59pp |
| 2013-12-31 | 5.36% | $27.26 Million | $508.65 Million | -21.28pp |
| 2012-12-31 | 26.64% | $37.74 Million | $141.65 Million | -11.14pp |
| 2011-12-31 | 37.78% | $62.11 Million | $164.37 Million | -17.17pp |
| 2010-12-31 | 54.95% | $47.83 Million | $87.03 Million | +8.08pp |
| 2009-12-31 | 46.87% | $42.92 Million | $91.58 Million | -16.16pp |
| 2008-12-31 | 63.03% | $59.93 Million | $95.08 Million | +14.56pp |
| 2007-12-31 | 48.47% | $39.09 Million | $80.64 Million | +16.19pp |
| 2006-12-31 | 32.28% | $16.98 Million | $52.62 Million | -45.32pp |
| 2005-12-31 | 77.60% | $51.51 Million | $66.38 Million | +2.60pp |
| 2004-12-31 | 75.00% | $17.15 Million | $22.87 Million | +24.24pp |
| 2003-12-31 | 50.76% | $24.21 Million | $47.69 Million | +13.30pp |
| 2002-12-31 | 37.47% | $8.68 Million | $23.18 Million | +7.46pp |
| 2000-12-31 | 30.01% | $2.62 Million | $8.73 Million | +14.27pp |
| 1999-12-31 | 15.74% | $3.53 Million | $22.43 Million | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more